EL7.AI
StocksMediumUpdated•Originally published 16 July 2026•Updated 17 July 2026•
2 min read

Citigroup to Redeem $1.5B in Preferred Stock as REGENXBIO Prices $90M Offering

Key Facts

1Citigroup announced the full redemption of its $1.5 billion aggregate liquidation preference of Series T Preferred Stock on August 15, 2026.
2REGENXBIO Inc. intends to offer and sell $100 million of its common stock in an underwritten public offering.

In a move reflecting divergent capital management strategies across the financial and biotech sectors, Citigroup has announced the full redemption of its $1.5 billion Series T Preferred Stock effective August 2026. Simultaneously, REGENXBIO Inc. has priced its public offering of 10,003,889 shares of common stock at $9.00 per share. The offering, which includes 1,111,111 pre-funded warrants priced at $8.9999, aims to raise fresh liquidity for general corporate purposes.

Citigroup's capital optimization comes amid a stable period for major lenders, with C shares closing at $134.89 (close July 15, 2026), compared to peers like JPMorgan (JPM) at $345.43 per market data. In the biotech space, pricing an offering at a specific level often sets a short-term floor or ceiling for the stock; REGENXBIO's $9.00 pricing will be a key benchmark for traders assessing the dilution impact compared to previous sector-wide capital raises.

Traders should monitor Citigroup's price action, which maintained a range between $131.77 and $135.12 as of the July 15, 2026 close. While the upcoming economic calendar shows no direct catalysts for these specific firms in the next week, broader market sentiment remains tied to upcoming U.S. monetary policy reports which could influence financing costs for both banking and healthcare sectors.